A healthy investment: Innovation in medtech as a driver of new investment opportunities

How data will prove key in sector's success

clock • 3 min read

Medical innovation has become a significant focus for the venture capital industry in the past ten years and the medical device industry is predicted to be worth more than $8.5bn by 2025.

However, making the right investment in a medical technology company at the right time is always a fine balance. In most circumstances companies need to have already established themselves within a specific market through their technology, product or service. At the same time, they need additional capital to accelerate growth and build on their achievements to date. This is particularly relevant in medtech market where innovation needs both time and money to prove itself clinically. Injecting new life: How to fill the gaping hole in support for R&D intensive businesses at late-s...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Alternatives

EY: Allocations to alternatives set to rise by almost a quarter in the next two years

EY: Allocations to alternatives set to rise by almost a quarter in the next two years

Global Alternative Funds survey

Sorin Dojan
clock 13 December 2024 • 2 min read
Hamilton Lane joins forces with Allfunds Blockchain to broaden tokenised access to private markets

Hamilton Lane joins forces with Allfunds Blockchain to broaden tokenised access to private markets

In collaboration with Apex Group

Linus Uhlig
clock 11 December 2024 • 2 min read
Refinitiv's Dewi John: There is little to no 'alternative'

Refinitiv's Dewi John: There is little to no 'alternative'

'Investors, clearly, remain unconvinced'

Dewi John
clock 11 December 2024 • 3 min read
Trustpilot